Sees FY24 Crysvita revenue in the range of $375M-$400M. This includes all regions where Ultragenyx will recognize revenue: product sales in Latin America and Turkey, royalties in Europe, which have been ongoing, and royalties in North America, which began in April 2023. Sees FY24 Dojolvi revenue in the range of $75M-$80M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RARE:
- Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
- RARE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
- Ultragenyx announces data demonstrating treatment with UX111
- Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
